Loading company…
Sunbird Bio develops blood-based diagnostic tests for neurological disorders and early-stage cancer.
Sunbird Bio develops molecular diagnostic tests for Alzheimer's disease, other neurological disorders and early-stage cancer. Its APEX platform detects low levels of disease-specific protein states in blood, while Glympse measures protease activity using peptide probes. Founded in 2021, the company is based in Massachusetts. In October 2024, it raised USD 14 million from EDBI and Eli Lilly & Company, with Clavystbio, Polaris Partners and Section 32 participating.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in